Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515 Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

CECRETARY OF THE SENATE
OF FEB 14 PM 4: 46

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

······································		
t. Registrant Name Williams & Jensen, PC	,	
	Suite 300 DC 20036	
Principal Place of Business (if different from line 2)	'	
City State/Zite (or Country)		
4. Contact Name Bentique Bentique Barbara W. Bontique 202-659-8201	il (optional) 5. Scrape ID # 41454-924	
7. Client Name ( ) Self  AstraZeneca Pharmaceuticals Group(formerly Zeneca)	6. House 10.4 30771057	
One Check if this filing amends a previously filed version of this One Check if this is a Termination Report  The State of the State of this is a Termination Report  The State of this is a Termina	n Date 11. No Lobbying Activity □	
12. Lobbying Firms	13. Organizations	
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reporting period were:	
Less than \$10,000 📋	Less thun \$10,000 ()	
\$10,000 or more 🔀 >> \$ \$40,000.00   	\$10,000 or more  >> \$  Expenses (nearest \$20,000)  14. REPORTING METHOD. Check box to indicate expense	
Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	accounting method. See instructions for description of options.	
	Method A. Reporting amounts using LDA definitions only	
	Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code	
	Method C. Reporting amounts under section 162(e) of the Internal Revenue Code	
Signature	Date 2/14/2981	
Finted Name and Title Barbara W. Bonfiglio - Attorney	Page 1 of 3	

<del>-</del>		
<del>-</del>	oup(formerly Zeneca)	
iged in lobbying on behalf of the client during the re rmation as requested. Attach additional page(s) as n	cessary to reflect the general issue areas in which the registrant eporting period. Using a separate page for each code, provide needed.	
General issue area code Specific Lebbying issues Pharmaceutical pricing		
House(s) of Congress and Federal agencies contact House of Representatives Senate	eted El Check if None	
Name of each individual who acted as a lobbyist in	n this issue area  Covered Official Position (if applicable)	New
Lynch, Karisa V.	Counsel to the Senate Perm. Subcomm. on Invest.	No
Olsen, George G.		No
Annual de la constanta de la c		
Interest of each foreign entity in the specific issues	s listed on line 16 above X Check if None	

Reg	istrant Name:	Williams & Jonson, PC				
Clie	nt Name;	AstraZeneca Pharmuceuticals Group(	formerly Zeneca)	•		
enge	iged in lobbyin		ry to reflect the general issue areas in which the registrant ing period. Using a separate page for each code, provide d.			
	15. General issue area code MMM (one per page)  16. Specific Lobbying issues  Medicare coverage and payment for prescription drugs  Reinportation of pharmaceuticals  Intellectual property protection for drugs					
<b>17.</b>	House(s) of C Senate House of Rep	ongress and Pederal agencies contacted presentatives	[3] Check if None			
18.	Name of each	individual who acted as a lobbyist in this	Covered Official Position (if applicable)	New		
_	Lynch, Karii	oa V.	Counsel to the Senate Perm. Subcomm. on Invest.	No		
	Olsen, Georg			No		
	Interest of each	is foreign entity in the specific issues liste	d on line 16 above   Check if None  Date 2/14/2091	· .		
Dein	od Nama and	rista Barbara W. Bonfiglio - Atloraev	- Bana	3 45 3		